stockrowCG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
Follow CGON
Alert me
CG Oncology, Inc. (CGON) EV/Sales
As of 6 November 2026, CG Oncology, Inc. (CGON) trades at a EV/Sales of 939×. Over the past ten years it has ranged from 0.0× (March 2024) to 3,525× (September 2025); the current reading is higher than 38% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 551× | (41.07%) |
| FY2024 | 936× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 864× | 2.49% |
| Jun 2026 | 843× | (7.24%) |
| Mar 2026 | 909× | 64.80% |
| Dec 2025 | 551× | (49.53%) |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | n/m |
| MANE Veradermics Incorporated compare | n/m |
| IMVT Immunovant, Inc. compare | n/m |
| KOD Kodiak Sciences Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 5.4× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 9.7× |
| LGND Ligand Pharmaceuticals Incorporated compare | 24.7× |
| SRRK Scholar Rock Holding Corporation compare | 120× |
| CGON CG Oncology, Inc. | 755× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement